Gonadorelin: Side Effects & Safety

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), structurally identical to the decapeptide hypothalamus secretes naturally. It was approved in the United States as Factrel (Wyeth/Ayerst) for diagnostic evaluation of pituitary gonadotropin function (LH/FSH response testing), and as Lutrepulse / Lutrelef for pulsatile delivery via portable pump in hypothalamic hypogonadism. The FDA label safety profile is well-characterized.^[1]

The defining safety paradox of gonadorelin: pulsatile dosing stimulates LH/FSH release; continuous dosing desensitizes the GnRH receptor and suppresses LH/FSH. This is the mechanism behind every GnRH agonist used clinically for chemical castration in prostate cancer and endometriosis (leuprolide, goserelin, triptorelin) — they continuously occupy the GnRH receptor and produce a hypogonadal state. The same molecule can do opposite things depending on how you dose it. The most common safety mistake in off-label use is inadvertent continuous dosing that suppresses rather than supports gonadal function.

Gonadorelin is not on the July 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list agenda — it does not need to be, because it has been FDA-approved as Factrel since 1982 and is a known compoundable substance.

Effect	Frequency (Factrel label)	Notes
Injection-site reactions (redness, soreness, induration)	Common (~1–3%)	Mild, self-limiting
Headache	Occasional	Usually transient
Flushing	Occasional	Transient warmth, vasomotor
Nausea	Rare (<1%)	Single-dose effect
Light-headedness	Rare	Usually positional
Abdominal discomfort	Rare	Mild and transient
Anaphylaxis / serious allergic reaction	Very rare (post-market)	Reported with repeat doses; severe enough to be on the FDA label
Antibody formation	Rare with chronic use	May reduce efficacy over time
Phlebitis (with continuous IV infusion)	Reported	Local irritation; rotate sites

The acute side-effect profile is mild compared with most peptides at therapeutic doses. The rare but documented anaphylaxis risk and the dosing-pattern paradox (pulsatile vs. continuous) are the two clinically meaningful safety considerations.

The FDA Factrel label includes warnings about hypersensitivity reactions including anaphylaxis, particularly on repeat exposures. Multiple case reports in the published literature describe anaphylactic reactions during stimulation testing or chronic pulsatile therapy.^[2] The first exposure is rarely problematic; the risk rises with repeat dosing as anti-gonadorelin antibodies can develop.

Practical implication: anyone using gonadorelin on a chronic schedule (off-label HPG axis maintenance during TRT, pulsatile fertility treatment) should have epinephrine access if there is any history of allergic reactions, and the first few doses are best administered where emergency care is available.

Native GnRH is released in pulses every 60–120 minutes. The pituitary gonadotrope responds to pulsatile signal with LH/FSH release. Continuous occupation of the GnRH receptor downregulates receptor density and the gonadotrope stops responding — circulating LH and FSH fall, downstream testosterone or estradiol fall, and the patient becomes functionally hypogonadal.

This is exactly how leuprolide (Lupron), goserelin (Zoladex), and triptorelin work in prostate cancer and endometriosis: they deliver continuous GnRH-receptor activation and produce chemical castration. Same receptor, same molecule family — different dosing pattern, opposite effect.

Off-label users sometimes try to maintain HPG axis function during TRT by adding gonadorelin doses too frequently or via slow-release formats that effectively produce continuous receptor occupation. The result is the opposite of the intent: suppression rather than maintenance of endogenous LH/FSH. If gonadorelin is being used to preserve HPG axis function, the dosing pattern must be physiological pulses (typically subcutaneous boluses every 60–120 minutes via pump, or specifically-spaced subcutaneous injections), not continuous or near-continuous exposure.

• Known hypersensitivity to gonadorelin or any GnRH analog.
• Hormone-responsive cancers (prostate, breast, endometrial, ovarian): chronic pulsatile gonadorelin increases LH/FSH and downstream sex hormones, which can stimulate hormone-responsive tumors. Continuous-dose GnRH agonists may be used in these cancers under oncology supervision — that is a separate clinical scenario.
• Pregnancy: generally contraindicated. Some pulsatile-pump fertility protocols use gonadorelin to induce ovulation in hypothalamic amenorrhea, but only under reproductive endocrinology supervision; not for general use.
• Breastfeeding: insufficient data; avoid.
• Pituitary adenomas, especially gonadotropin-secreting: may worsen.
• History of severe allergic reactions to peptide medications.

Drug interactions

• GnRH agonists (leuprolide, goserelin, triptorelin): opposite mechanism by virtue of dosing pattern. Do not combine.
• Androgens, anabolic steroids, exogenous testosterone: exogenous androgens already suppress the HPG axis via negative feedback. Adding gonadorelin while on a suppressive androgen dose does not "rescue" the axis if the suppressive driver (the exogenous androgen) is still present.
• Aromatase inhibitors / SERMs (clomiphene, tamoxifen): these also affect HPG signaling. Combinations require endocrinology oversight.
• Dopamine agonists, glucocorticoids, sex hormones: all can alter the LH/FSH response and may confound diagnostic testing.

• Mild injection-site reaction: rotate sites; resolves within 24–48 hours.
• Flushing, headache, light-headedness: hydrate, lie down if needed; usually transient.
• Hives, swelling, breathing difficulty, throat tightness: stop immediately and seek emergency care — anaphylaxis risk is on the FDA label.
• Falling rather than rising testosterone / LH on repeated testing: this is the pulsatile-vs-continuous paradox; the dosing pattern is too dense and is downregulating the receptor. Increase the dose interval (rather than decrease the dose), or pause and re-evaluate the protocol.
• Loss of effect over months: consider antibody formation; switch protocols or take a wash-out period.

See the gonadorelin complete guide, dosage protocols, benefits and research, and the peptides for sexual health overview.